# Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

> **NCT01871558** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Metformin
- **DRUG:** sulfonylurea (SU)
- **DRUG:** Basal Insulin

## Key facts

- **NCT ID:** NCT01871558
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871558, "Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT01871558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*